Journal: Nature Communications

Article Title: Synapse type-specific proteomic dissection identifies IgSF8 as a hippocampal CA3 microcircuit organizer

doi: 10.1038/s41467-020-18956-x

Figure Lengend Snippet:

Article Snippet: Primary antibodies were the following: mouse anti-PSD95 (1:2500; Thermo-Fisher), rabbit ant-Synaptophysin (1:2500; Sigma-Aldrich), rabbit anti-Synpr (1:2500; Synaptic Systems), rabbit anti-Nectin3 (1:500; Abcam), goat anti-MBP (1:500; Santa Cruz), rabbit anti-Histone H3 (1:1000; Cell Signaling Technology), goat anti-IgSF8 (1:2000; R&D Systems), mouse anti-TenR (1:1000; R&D Systems), rabbit anti-BRINP2 (1:100; Atlas Antibodies), sheep anti-CNTN1 (1:500; R&D Systems), goat anti-ICAM5 (1:500; R&D Systems), sheep anti-ISLR2 (1:1000; R&D Systems), goat anti-Kit/SCFR (1:1000; R&D Systems), goat anti-NEGR1 (1:1000; R&D Systems), goat anti-Neogenin (1:1000; R&D Systems), goat anti-NRP1 (1:500; R&D Systems), goat anti-PlexinA1 (1:500; R&D Systems), rabbit anti-PTPRD (1:500; Novus), goat anti-PTPRS (1:1000; R&D Systems), rabbit anti-ROBO2 (1:1000; Abcam), and sheep anti-Teneurin-4 (1:1000; R&D Systems).

Techniques: Virus, Plasmid Preparation, Recombinant, Transfection, Antibody Labeling, Cloning, Suspension, Cell Culture, Knock-Out, Software, Microscopy

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: Assay of sICAM5 in plasma from epilepsy patients and controls . (A) Dot-plot of sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is significant for p = 0.002. (C) ROC curve for data in Part a, showing an area under the curve (AUC) value of 0.87.

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: Levels of cytokines and chemokines in plasma that significantly distinguish between epilepsy patients and controls .

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics, Concentration Assay

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: IL-6/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of IL-6/sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is not significant, with p = 0.087. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 0.90.

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: IL-8/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of IL-8/sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference not significant, with p = 0.125. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 0.88.

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: TARC/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of TARC/sICAM5 concentrations in plasma (square, patients; diamond, controls). There are no values between the horizontal lines, indicating the assay accurately discriminates between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is 13-fold, and is significant for p = 0.034. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 1.00.

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics